Select Page

Autoimmune Dry Eye

Autoimmune disorders involve the body’s immune system mistakenly reacting to the tissues in one’s own body. They are all chronic inflammatory diseases, which often progress to more complex, systemic disorders that can affect other tissues and organs in the body. In the links at right, we will take a look at each of these disorders to better understand how the ocular surface in autoimmune dry eye responds in reaction to the inflammatory cascade, what the conventional clinical management practices are, and how TheraLife® can help.

TheraLife Eye Autoimmune

TheraLife Autoimmune

For autoimmune dry eye from Sjogren’s syndrome, rheumatoid arthritis, ocular rosacea, Graves’ disease, Raynaud’s, lupus, bone marrow transplantation, graft versus host disease, and more.

2 bottles for $74.95

Call And Talk To A Doctor And See If TheraLife Autoimmune Is Right For You.  1-877-917-1989 US/Canaada. 

Buy Now

Autoimmune Dry Eye

References

1.Socié G, Ritz J. Current issues in chronic graft-versus-host disease. Blood. 2014 Jul 17;124(3):374-84. [PMC free article] [PubMed]
2.Antin JH, Kim HT, Cutler C, Ho VT, Lee SJ, Miklos DB, Hochberg EP, Wu CJ, Alyea EP, Soiffer RJ. Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation. Blood. 2003 Sep 01;102(5):1601-5. [PubMed]
3.Shimabukuro-Vornhagen A, Liebig T, von Bergwelt-Baildon M. Statins inhibit human APC function: implications for the treatment of GVHD. Blood. 2008 Aug 15;112(4):1544-5. [PubMed]
4.Mielcarek M, Martin PJ, Leisenring W, Flowers ME, Maloney DG, Sandmaier BM, Maris MB, Storb R. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood. 2003 Jul 15;102(2):756-62. [PubMed]
5.Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet. 2009 May 02;373(9674):1550-61. [PMC free article] [PubMed]
6.Jamil MO, Mineishi S. State-of-the-art acute and chronic GVHD treatment. Int J Hematol. 2015 May;101(5):452-66. [PubMed]
7.Atkinson K, Horowitz MM, Gale RP, van Bekkum DW, Gluckman E, Good RA, Jacobsen N, Kolb HJ, Rimm AA, Ringdén O. Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood. 1990 Jun 15;75(12):2459-64. [PubMed]
8.MacMillan ML, Robin M, Harris AC, DeFor TE, Martin PJ, Alousi A, Ho VT, Bolaños-Meade J, Ferrara JL, Jones R, Arora M, Blazar BR, Holtan SG, Jacobsohn D, Pasquini M, Socie G, Antin JH, Levine JE, Weisdorf DJ. A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality. Biol Blood Marrow Transplant. 2015 Apr;21(4):761-7. [PMC free article] [PubMed]
9.Gale RP, Bortin MM, van Bekkum DW, Biggs JC, Dicke KA, Gluckman E, Good RA, Hoffmann RG, Kay HE, Kersey JH. Risk factors for acute graft-versus-host disease. Br J Haematol. 1987 Dec;67(4):397-406. [PubMed]
10.Nassereddine S, Rafei H, Elbahesh E, Tabbara I. Acute Graft Versus Host Disease: A Comprehensive Review. Anticancer Res. 2017 Apr;37(4):1547-1555. [PubMed]

More References

  • 1.Dry eye as a mucosal autoimmune disease. Stern ME, Schaumburg CS, Pflugfelder SC. Int Rev Immunol. 2013;32:19–41. doi: 10.3109/08830185.2012.748052. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.TFOS DEWS II report executive summary. Craig JP, Nelson JD, Azar DT, et al. Ocul Surf. 2017;15:802–812. doi: 10.1016/j.jtos.2017.08.003. [DOI] [PubMed] [Google Scholar]
  • 3.The definition and classification of dry eye disease. https://www.tearfilm.org/pdfs/OM%20-%20Definition%20. Ocul Surf. 2007;5:75–92. doi: 10.1016/s1542-0124(12)70081-2. [DOI] [PubMed] [Google Scholar]
  • 4.TFOS DEWS II definition and classification report. Craig JP, Nichols KK, Akpek EK, et al. Ocul Surf. 2017;15:276–283. doi: 10.1016/j.jtos.2017.05.008. [DOI] [PubMed] [Google Scholar]
  • 5.TFOS DEWS II diagnostic methodology report. Wolffsohn JS, Arita R, Chalmers R, et al. Ocul Surf. 2017;15:539–574. doi: 10.1016/j.jtos.2017.05.001. [DOI] [PubMed] [Google Scholar]
  • 6.TFOS DEWS II management and therapy report. Jones L, Downie LE, Korb D, et al. Ocul Surf. 2017;15:575–628. doi: 10.1016/j.jtos.2017.05.006. [DOI] [PubMed] [Google Scholar]
  • 7.TFOS DEWS II pathophysiology report. Bron AJ, de Paiva CS, Chauhan SK, et al. Ocul Surf. 2017;15:438–510. doi: 10.1016/j.jtos.2019.08.007. [DOI] [PubMed] [Google Scholar]
  • 8.TFOS DEWS II iatrogenic report. Gomes JA, Azar DT, Baudouin C, et al. Ocul Surf. 2017;15:511–538. doi: 10.1016/j.jtos.2017.05.004. [DOI] [PubMed] [Google Scholar]
  • 9.Inflammation and dry eye disease-where are we? Rao SK, Mohan R, Gokhale N, Matalia H, Mehta P. Int J Ophthalmol. 2022;15:820–827. doi: 10.18240/ijo.2022.05.20. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Effectiveness of mediterranean diet implementation in dry eye parameters: a study of PREDIMED-PLUS trial. Molina-Leyva I, Molina-Leyva A, Riquelme-Gallego B, Cano-Ibáñez N, García-Molina L, Bueno-Cavanillas A. Nutrients. 2020;12 doi: 10.3390/nu12051289. [DOI] [PMC free article] [PubMed] [Google Scholar]

Pin It on Pinterest